Tang Capital Management LLC Decreases Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Tang Capital Management LLC lowered its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 2.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,850,000 shares of the biopharmaceutical company’s stock after selling 50,000 shares during the period. Dynavax Technologies accounts for 1.6% of Tang Capital Management LLC’s investment portfolio, making the stock its 16th biggest holding. Tang Capital Management LLC owned approximately 1.41% of Dynavax Technologies worth $23,624,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of DVAX. Deep Track Capital LP increased its stake in shares of Dynavax Technologies by 42.0% during the 4th quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company’s stock worth $227,197,000 after purchasing an additional 5,265,000 shares during the last quarter. Deerfield Management Company L.P. Series C increased its stake in shares of Dynavax Technologies by 23,990.1% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 5,193,823 shares of the biopharmaceutical company’s stock worth $66,325,000 after purchasing an additional 5,172,263 shares during the last quarter. Norges Bank purchased a new stake in shares of Dynavax Technologies during the 4th quarter worth approximately $7,762,000. D. E. Shaw & Co. Inc. increased its stake in shares of Dynavax Technologies by 34.0% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,918,340 shares of the biopharmaceutical company’s stock worth $24,497,000 after purchasing an additional 486,981 shares during the last quarter. Finally, WINTON GROUP Ltd increased its stake in shares of Dynavax Technologies by 339.0% during the 4th quarter. WINTON GROUP Ltd now owns 426,814 shares of the biopharmaceutical company’s stock worth $5,450,000 after purchasing an additional 329,579 shares during the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on DVAX. The Goldman Sachs Group decreased their price target on shares of Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating for the company in a research note on Thursday, April 17th. HC Wainwright reiterated a “buy” rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research note on Friday, February 21st. JMP Securities reduced their price objective on shares of Dynavax Technologies from $33.00 to $31.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 7th. StockNews.com lowered shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, May 6th. Finally, William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $24.00.

Dynavax Technologies Stock Up 1.7%

Dynavax Technologies stock opened at $9.67 on Friday. The firm has a 50 day simple moving average of $11.78 and a 200 day simple moving average of $12.51. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of 53.72 and a beta of 1.26. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a 1-year low of $9.22 and a 1-year high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.14). The firm had revenue of $68.16 million for the quarter, compared to analysts’ expectations of $70.01 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. On average, analysts predict that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.